How QSR Postmarket Surveillance Will Evolve Under the QMSR
As medical device manufacturers transition from the FDA’s Quality System Regulation (QSR) to the new Quality Management System Regulation (QMSR), one area undergoing significant change is postmarket surveillance.
Under the QSR, postmarket activities such as complaint handling and Medical Device Reporting (MDR) were treated as largely reactive compliance functions. With the QMSR’s incorporation of ISO 13485:2016, however, the emphasis shifts toward a more proactive, risk-based, and integrated approach to monitoring product performance once devices reach the market.
This evolution brings U.S. requirements into closer alignment with global expectations—particularly those in the EU and other markets—while raising the bar for how manufacturers detect, analyze, and respond to postmarket signals.
To prepare for QMSR compliance, companies will need to strengthen their quality feedback systems, refine data analysis practices, and ensure that complaint trends are linked to broader quality system processes like risk management and CAPA.
Major Differences Between QSR and QMSR PMS Expectations
Structure and Integration
QSR = Fragmented across complaint handling, CAPA, servicing, etc.
QMSR = Integrates PMS into a cohesive, risk-based quality management structure.
Proactivity
QSR = Primarily reactive (responding to complaints, failures).
QMSR = Adds proactive feedback, data analysis, and trend monitoring as formal expectations.
Global Alignment
QSR = U.S.-centric focus.
QMSR/ISO 13485 = Aligned with global regulatory expectations (EU MDR, MDSAP), supporting international compliance.
Documentation and Planning
QSR = No PMS plan or structured documentation required.
QMSR = Although ISO 13485 doesn’t use the term “PMS plan,” documented procedures are required, and planning consistent with EU-style PMS plans is considered best practice.
Buy the Book